Awareness and Utilization of BRCA1/2 Testing Among US Primary Care Physicians

被引:118
作者
Bellcross, Cecelia A. [1 ]
Kolor, Katherine [1 ]
Goddard, Katrina A. B. [2 ]
Coates, Ralph J. [1 ]
Reyes, Michele [1 ]
Khoury, Muin J. [1 ]
机构
[1] Ctr Dis Control & Prevent, Off Publ Hlth Genom, CDC, Atlanta, GA 30333 USA
[2] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA
关键词
OVARIAN-CANCER SUSCEPTIBILITY; GENETIC RISK-ASSESSMENT; MUTATION CARRIERS; BREAST-CANCER; SALPINGO-OOPHORECTOMY; FAMILY PHYSICIANS; NATIONAL-SURVEY; METAANALYSIS; STATEMENT; KNOWLEDGE;
D O I
10.1016/j.amepre.2010.09.027
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Testing for mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 (BRCA) has been commercially available since 1996. Purpose: This study sought to determine, among U. S. primary care physicians, the level of awareness and utilization of BRCA testing and the 2005 U. S. Preventive Services Task Force (USPSTF) recommendations. Methods: In 2009, data were analyzed on 1500 physician respondents to the 2007 DocStyles national survey (515 family practitioners, 485 internists, 250 pediatricians, and 250 obstetricians/gynecologists). Results: Overall, 87% of physicians were aware of BRCA testing, and 25% reported having ordered testing for at least one patient in the past year. Ordering tests was most prevalent among obstetricians/gynecologists in practice for more than 10 years, with more affluent patients. Physicians were asked to select indications for BRCA testing from seven different clinical scenarios representing increased (4) or low-risk (3) situations consistent with the USPSTF guidelines. Among ordering physicians (pediatricians excluded), 45% chose at least one low-risk scenario as an indication for BRCA testing. Only 19% correctly selected all of the increased-risk and none of the low-risk scenarios. Conclusions: A substantial majority of primary care physicians are aware of BRCA testing and many report having ordered at least one test within the past year. A minority, however, appear to consistently recognize the family history patterns identified by the USPSTF as appropriate indications for BRCA evaluation. These results suggest the need to improve providers' knowledge about existing recommendations-particularly in this era of increased BRCA direct-to-consumer marketing. (Am J Prev Med 2011; 40(1): 61-66) (C) 2011 American Journal of Preventive Medicine
引用
收藏
页码:61 / 66
页数:6
相关论文
共 23 条
[1]   Clinical genetics issues encountered by family physicians [J].
Acheson, LS ;
Stange, KC ;
Zyzanski, S .
GENETICS IN MEDICINE, 2005, 7 (07) :501-508
[2]  
*AM COLL MED GEN F, GEN SUSC BREAST OV C
[3]  
American Society of Breast Surgeons, BRCA GEN TEST PAT BR
[4]  
[Anonymous], 2009, Obstet Gynecol, V113, P957
[5]  
[Anonymous], CLIN PRACT GUID ONC
[6]   Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility:: Recommendation statement [J].
Berg, AO ;
Allan, JD ;
Calonge, N ;
Frame, PS ;
Gordis, L ;
Gregory, KD ;
Harris, R ;
Johnson, MS ;
Klein, JD ;
Loveland-Cherry, C ;
Moyer, VA ;
Ockene, JK ;
Petitti, DB ;
Siu, AL ;
Teutsch, SM ;
Yawn, BP .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (05) :355-361
[7]   Psychological impact of genetic counseling for familial cancer: A systematic review and meta-analysis [J].
Braithwaite, D ;
Emery, J ;
Walter, F ;
Prevost, AT ;
Sutton, S .
FAMILIAL CANCER, 2006, 5 (01) :61-75
[8]   American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility [J].
Bruinooge, SS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2397-2406
[9]   Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? [J].
Doksum, T ;
Bernhardt, BA ;
Holtzman, NA .
GENETICS IN MEDICINE, 2003, 5 (02) :99-105
[10]   Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers:: a prospective cohort study [J].
Domchek, SM ;
Friebel, TM ;
Neuhausen, SL ;
Wagner, T ;
Evans, G ;
Isaacs, C ;
Garber, JE ;
Daly, M ;
Eeles, R ;
Matloff, E ;
Tomlinson, GE ;
Van't Veer, L ;
Lynch, HT ;
Olopade, O ;
Weber, BL ;
Rebbeck, TR .
LANCET ONCOLOGY, 2006, 7 (03) :223-229